MedAvail (NASDAQ:MDVL) Trading Down 40.6%

MedAvail Holdings, Inc. (NASDAQ:MDVLGet Free Report) shares were down 40.6% on Monday . The stock traded as low as $1.74 and last traded at $1.80. Approximately 245,100 shares traded hands during mid-day trading, a decline of 6% from the average daily volume of 261,432 shares. The stock had previously closed at $3.03.

MedAvail Stock Down 40.6 %

The company has a market capitalization of $2.91 million, a price-to-earnings ratio of -0.06 and a beta of 0.76. The business’s 50-day moving average is $3.37 and its 200-day moving average is $5.05.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Alyeska Investment Group L.P. acquired a new position in MedAvail during the first quarter worth $5,572,000. Millennium Management LLC grew its holdings in shares of MedAvail by 148.3% in the second quarter. Millennium Management LLC now owns 224,873 shares of the company’s stock valued at $344,000 after purchasing an additional 134,315 shares during the period. Virtu Financial LLC purchased a new stake in shares of MedAvail in the second quarter valued at about $42,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of MedAvail in the 3rd quarter valued at approximately $31,000.

MedAvail Company Profile

(Get Free Report)

MedAvail Holdings, Inc, a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist.

Featured Stories

Receive News & Ratings for MedAvail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedAvail and related companies with's FREE daily email newsletter.